Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension

Blanco, Susana; Vaquero, Manuel; Gómez-Guerrero, Carmen; López, Dolores; Egido, Jesús; Romero, R.

doi:10.1016/j.amjhyper.2004.10.034

Cited by 62 publications

(47 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, animal studies have demonstrated that combining statins and ACEI resulted in improved renal function; remarkable antiproteinuric effect; and less glomerulosclerosis, tubular damage, interstitial inflammation, and podocyte damage (30,31). These results are also supported by a previous clinical study that suggested that atorvastatin in addition to ACEI or angiotensin AT1 receptor antagonists reduce proteinuria and the rate of progression of kidney disease in patients with chronic kidney disease, proteinuria, and hypercholesterolemia (32).…”

Section: Combined Use Of Statins and Aceimentioning

confidence: 76%

Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors

Feringa¹,

Karagiannis²,

Chonchol³

et al. 2007

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Patients with peripheral arterial disease (PAD) are at increased risk for ESRD and cardiovascular events. The primary objective was to assess the association between ankle-brachial index (ABI) values and renal outcome. The secondary objective was to evaluate whether statins and angiotensin-converting enzyme inhibitors (ACEI) are associated with improved renal and cardiovascular outcome in patients with PAD. In a prospective observational cohort study of 1940 consecutive patients with PAD, ABI was measured and chronic statin and ACEI therapy was noted at baseline. Serial creatinine concentrations were obtained at baseline, 6 mo, and every year after enrollment. End points were ESRD, all-cause mortality, and cardiac events during a median follow-up period of 8 yr. Baseline estimated GFR <60 ml/min per 1.73 m 2 was assessed in 27% of patients. ESRD, all-cause mortality, and cardiac events occurred in 10, 46, and 31% of patients, respectively. In multivariate analysis, a lower baseline ABI was significantly associated with a higher progression rate of ESRD (hazard ratio [

show abstract

Section: Combined Use Of Statins and Aceimentioning

confidence: 76%

Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors

Feringa¹,

Karagiannis²,

Chonchol³

et al. 2007

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Furthermore, polymorphisms associated with the NF-B binding sites in the promoter for CCL5/RANTES are reported to be a risk factor for the development of DN in patients with type 2 diabetes (25). For CXCL10/IP-10, an increased interstitial staining signal has been reported in obese diabetic Zucker rats, a model of diabetes-related nephropathy (26). These results suggest a general role for these chemokines in the inflammatory tubulointerstitial infiltrate of progressive DN.…”

Section: Discussionmentioning

confidence: 88%

Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy

et al. 2006

View full text Add to dashboard Cite

“…In particular, the use of a different class of drugs, such as ACE inhibitors captopril, lisinopril, fosinopril, benazapril and quinapril, and AT-Ⅰ receptor blockers, such as losartan, olmesartan and irbesartan, have been observed in numerous experimental and clinical studies to have therapeutic potential in the treatment of diabetic nephropathy [69][70][71][72][73][74][75][76][77] . Captopril was the first drug approved by Food and Drug Administration in the nineties for the treatment of diabetic nephropathy [48] .…”

Section: Pharmacological Interventions To Treat Diabetic Smokers Withmentioning

confidence: 99%

Smoking in diabetic nephropathy: sparks in the fuel tank?

Chakkarwar¹

2012

WJD

View full text Add to dashboard Cite

Diabetic nephropathy is associated with high morbidity and mortality and the prevalence of this disease is continuously increasing worldwide. Long-term diabetes increases the likelihood of developing secondary complications like nephropathy, the most common cause of end stage renal disease. Usually, other factors like hypertension, alcoholism and smoking also partly contribute to the progression of diabetic nephropathy. Among this, cigarette smoking in diabetes has been repeatedly confirmed as an independent risk factor for the onset and progression of diabetic nephropathy. Various studies suggest that smoking is a major fuel in the development of high oxidative stress and subsequently hyperlipidemia, accumulation of advanced glycation end products, activation of the renin angiotensin system and Rho-kinase, which are observed to play a pathogenic role in the progression of diabetic nephropathy. Furthermore, cigarette smoking in diabetic patients with vascular complications produces a variety of pathological changes in the kidney, such as thickening of the glomerular basement membrane and mesangial expansion with progression in glomerulosclerosis and interstitial fibrosis, which ultimately results in end stage renal failure. Strong associations are consistently found between chronic cigarette smoking and diabetic microvascular complications. A diverse group of studies unveil potential mechanisms that may explain the role of cigarette smoking in the progression of diabetic nephropathy. Tremendous efforts are being made to control smoking mediated progression of diabetic nephropathy, but no promising therapy is yet available. The present review critically discusses the possible detrimental role of chronic cigarette smoking in the progression of diabetic nephropathy and various possible pharmacological interventions to attenuate the exacerbation of diabetic nephropathy.

show abstract

Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension

Cited by 62 publications

References 27 publications

Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors

Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors

Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy

Smoking in diabetic nephropathy: sparks in the fuel tank?

Contact Info

Product

Resources

About